Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy tr...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

TheDragonsClaw Jun. 4 at 9:27 AM

$SEGG $CPIX $IBO $EVAX Need more news!

0 · Reply

haha1978 Jun. 2 at 7:25 PM

$CPIX if scleroderma is good then its 3 possible sectors and will be a platform play.

0 · Reply

STACKD0E Jun. 2 at 3:46 PM

$CPIX

0 · Reply

cmeola1066 Jun. 2 at 2:42 PM

$CADL $CPIX $QQQ $SLS $XBI Well well well! BULLISH‼️💯

2 · Reply

haha1978 Jun. 2 at 2:37 PM

$CPIX look at that a new drug that will stop cancer metastasis unbelievable. Not bad for a well run company. $SLS $CADL $XBI $QQQ https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-and-vanderbilt-health-announce-potential-new-therapy-to-prevent-cancer-metastasis-302788251.html

3 · Reply

focafoca99 Jun. 2 at 1:29 PM

$CPIX presented Phase 2a trial data showing ifetroban is safe and hints at reduced metastatic recurrence.

0 · Reply

Stock_Catcher Jun. 2 at 1:05 PM

$CPIX Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

0 · Reply

haha1978 Jun. 1 at 7:20 PM

$CPIX gap at 6.15. Algorithm for got to fill it this morning. Shows on the hourly. Maybe later this week.

0 · Reply

haha1978 Jun. 1 at 5:08 PM

$CPIX shaking it before the scleroderma data? Must be good. Its also the 1st day of the month. Monthly chart gap filled so we will see were this ends up by june 30th. The vote results are june 24th.

1 · Reply

clan Jun. 1 at 12:36 PM

$AZN ⚠️ Great news for diabetic kiddos ! ! ! 👍👍 FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 🚫💉 No needles! $CPIX $PLRX $GRI

0 · Reply

Cumberland announces data from Phase 2a clinical trial of ifetroban

Jun 2, 2026, 9:05 AM EDT - 2 days ago

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Jun 2, 2026, 8:00 AM EDT - 2 days ago

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

RDHL

2026-05-28T14:51:26.000Z - 7 days ago

Cumberland announces launch of Vibativ in China

May 28, 2026, 9:05 AM EDT - 7 days ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

May 26, 2026, 8:00 AM EDT - 9 days ago

Cumberland Pharmaceuticals Proxy statement: Proxy filing

May 15, 2026, 8:00 AM EDT - 20 days ago

Cumberland Pharmaceuticals Proxy statement: Proxy filing

May 5, 2026, 5:00 PM EDT - 4 weeks ago

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

May 5, 2026, 4:30 PM EDT - 4 weeks ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 weeks ago

Cumberland Pharmaceuticals Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 4 weeks ago

Cumberland Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 5 weeks ago

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

RDHL

Apr 28, 2026, 4:05 PM EDT - 5 weeks ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

RDHL

2026-04-23T13:13:38.000Z - 6 weeks ago

Cumberland announces transaction to integrate commercial business with Apotex

Apr 23, 2026, 9:00 AM EDT - 6 weeks ago

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Cumberland Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

RDHL

2026-04-16T13:58:04.000Z - 7 weeks ago

Cumberland receives FDA approval for expanded Caldolor injection

Apr 16, 2026, 9:05 AM EDT - 7 weeks ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

2026-03-17T13:21:41.000Z - 2 months ago

Cumberland announces launch of new Sancuso website

Mar 17, 2026, 9:05 AM EDT - 2 months ago

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 3, 2026, 5:00 PM EST - 3 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Mar 3, 2026, 4:30 PM EST - 3 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:30 PM EST - 3 months ago

Cumberland Pharmaceuticals Annual report: Q4 2025

Mar 3, 2026, 4:30 PM EST - 3 months ago

Cumberland Pharmaceuticals Earnings release: Q4 2025

Mar 3, 2026, 4:30 PM EST - 3 months ago

Cumberland Pharmaceuticals Annual report: Q4 2025

2026-02-25T12:20:11.000Z - 3 months ago

Cumberland and THI announce U.S. commercialization of Talicia

2026-02-25T12:17:19.000Z - 3 months ago

RedHill Biopharma announces full sales and operational launch of Talicia

RDHL

Feb 25, 2026, 7:00 AM EST - 3 months ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

RDHL

Feb 25, 2026, 7:00 AM EST - 3 months ago

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

Feb 24, 2026, 4:05 PM EST - 3 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

2026-02-04T14:11:54.000Z - 4 months ago

Cumberland receives fast track designation for DMD oral therapy from FDA

Feb 4, 2026, 9:05 AM EST - 4 months ago

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Dec 8, 2025, 9:05 AM EST - 6 months ago

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 5:00 PM EST - 7 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Nov 4, 2025, 4:30 PM EST - 7 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Cumberland Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Cumberland Pharmaceuticals Earnings release: Q3 2025

Oct 28, 2025, 4:05 PM EDT - 7 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

2025-10-20T13:05:16.000Z - 8 months ago

RedHill Biopharma signs strategic partnership with Cumberland

RDHL

Oct 20, 2025, 9:05 AM EDT - 8 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 8 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

2025-10-13T13:10:36.000Z - 8 months ago

Cumberland adds Vibativ to national group purchasing agreement with Premier

Oct 13, 2025, 9:05 AM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

2025-10-01T13:10:20.000Z - 8 months ago

Cumberland says ibuprofen injection product gets regulatory approval in Mexico

Oct 1, 2025, 9:05 AM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

2025-09-29T13:10:14.000Z - 8 months ago

Cumberland announces launch of Vibativ injection in Saudi Arabia

Sep 29, 2025, 9:05 AM EDT - 8 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 5, 2025, 4:30 PM EDT - 10 months ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 10 months ago

Cumberland Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 10 months ago

Cumberland Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

2025-08-04T13:10:32.000Z - 10 months ago

Cumberland announces availability of Vibativo 4-Vial Starter Pak through Vizient

Aug 4, 2025, 9:05 AM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 11 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

2025-06-23T17:50:52.000Z - 1 year ago

Cumberland shares latest results from its Phase 2 FIGHT DMD trial

Jun 23, 2025, 9:05 AM EDT - 1 year ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 1 year ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

2025-05-13T20:22:40.000Z - 1 year ago

Cumberland announces partnership with Qureight

May 13, 2025, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 6, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q1 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 1 year ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 4, 2025, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q4 2024

Mar 4, 2025, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

2025-02-18T12:39:36.000Z - 1 year ago

Cumberland announces NMPA approval of Vibativ injection in China

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

2025-02-04T12:36:58.000Z - 1 year ago

Cumberland reports ‘positive’ results from Phase 2 FIGHT DMD trial

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Cumberland Pharmaceuticals Earnings release: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 7, 2024, 4:30 PM EDT - 2 years ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

Cumberland Pharmaceuticals Quarterly report: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

Cumberland Pharmaceuticals Earnings release: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 2 years ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Cumberland Pharmaceuticals Proxy statement: Proxy Filing

Mar 5, 2024, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 5, 2024, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Annual report: Q4 2023

Mar 5, 2024, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Earnings release: Q4 2023

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Dec 14, 2023, 7:00 AM EST - 2 years ago

Cumberland Pharmaceuticals Registration statement: Registration Filing

Nov 7, 2023, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 7, 2023, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Quarterly report: Q3 2023

Nov 7, 2023, 4:30 PM EST - 2 years ago

Cumberland Pharmaceuticals Earnings release: Q3 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

TheDragonsClaw Jun. 4 at 9:27 AM

$SEGG $CPIX $IBO $EVAX Need more news!

0 · Reply

haha1978 Jun. 2 at 7:25 PM

$CPIX if scleroderma is good then its 3 possible sectors and will be a platform play.

0 · Reply

STACKD0E Jun. 2 at 3:46 PM

$CPIX

0 · Reply

cmeola1066 Jun. 2 at 2:42 PM

$CADL $CPIX $QQQ $SLS $XBI Well well well! BULLISH‼️💯

2 · Reply

haha1978 Jun. 2 at 2:37 PM

3 · Reply

focafoca99 Jun. 2 at 1:29 PM

$CPIX presented Phase 2a trial data showing ifetroban is safe and hints at reduced metastatic recurrence.

0 · Reply

Stock_Catcher Jun. 2 at 1:05 PM

$CPIX Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

0 · Reply

haha1978 Jun. 1 at 7:20 PM

$CPIX gap at 6.15. Algorithm for got to fill it this morning. Shows on the hourly. Maybe later this week.

0 · Reply

haha1978 Jun. 1 at 5:08 PM

$CPIX shaking it before the scleroderma data? Must be good. Its also the 1st day of the month. Monthly chart gap filled so we will see were this ends up by june 30th. The vote results are june 24th.

1 · Reply

clan Jun. 1 at 12:36 PM

0 · Reply

haha1978 Jun. 1 at 8:23 AM

$CPIX looking for a break of 7 this week the closer we get to the june 24th vote eventually might hit a new 52 week high to 10.

0 · Reply

biotechdollars May. 31 at 1:53 AM

$CPIX Algos account for 80% ish volume large caps. Wouldnt think algos trade microcaps. In any event cpix can go up or short term. Within months, multip study ifetroban.

0 · Reply

haha1978 May. 29 at 3:49 PM

$CPIX looking for a 6.25 print eod.

0 · Reply

haha1978 May. 29 at 3:01 AM

$CPIX $CPIX ast friday we went up 40 cents what sbout this friday?

0 · Reply

PrayTradeRepeat May. 28 at 2:54 PM

$CPIX 1 HOUR TELLS THE TRUTH. FALSE ALARM. ALL IS WELL.

0 · Reply

PrayTradeRepeat May. 28 at 2:46 PM

$CPIX the core issue: the market may simply not care about pipeline optionality until real clinical proof arrives. The market does not assign cash value to cash, opertaing costs, pipeline in biotech do not get the benefit of the doubt. This may be the ceiling..? Back to 3.60 to coil again for another month is a possibility? New here?

0 · Reply

PrayTradeRepeat May. 28 at 2:25 PM

$CPIX ?

0 · Reply

PrayTradeRepeat May. 27 at 3:02 PM

$CPIX

0 · Reply

PrayTradeRepeat May. 27 at 1:56 PM

$CPIX Look at the bid/ask on Yahoo right now: bid: 4.26 ask: 7.69

1 · Reply

Dogfon May. 26 at 8:09 PM

$CPIX Hold !! This was a shake out..

0 · Reply

PrayTradeRepeat May. 26 at 8:05 PM

$CPIX Was that a sell-off or a short attack and why? I held through all of it. 7.24 next stop.. then, 8, 9, 10, 11, 12...

1 · Reply

Dogfon May. 26 at 4:06 PM

$CPIX Facts matter https://clinicaltrials.gov/study/NCT02682511?utm_source=copilot.com

0 · Reply

Market Cap	86.45M
Revenue (ttm)	44.52M
Net Income (ttm)	-2.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.38%
Debt to Equity Ratio	0.25

Volume	23,200
Avg Vol	1,206,072
Day's Range	N/A - N/A
Shares Out	14.98M
Stochastic %K	71%
Beta	0.09
Analysts	Strong Buy
Price Target	$8.50